At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
LY2216684 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of LY2216684 on the Pharmacokinetics of Theophylline in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2216684 and Theophylline for Major Depressive Disorder. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedDec 20, 2010
Enrollment StartDec 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.5 years ago
Interventions
LY2216684drug
18-mg LY2216684 oral dose
Theophyllinedrug
200-mg theophylline oral dose